Home › Steatotic Liver Disease › Missouri › Kansas City
Steatotic Liver Disease clinical trials in Kansas City, MO
4 studies for Steatotic Liver Disease are looking for participants at sites in and around Kansas City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
RecruitingPhase 3
- AMR Clinical, Kansas City
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RecruitingPhase 3
- Akero Clinical Study Site, Kansas City
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
RecruitingPhase 3
- GSK Investigational Site, Kansas City
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
RecruitingPhase 2
- GSK Investigational Site, Kansas City
About Steatotic Liver Disease
Steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in your liver. Learn about the causes and treatments.
More about Steatotic Liver Disease on MedlinePlus
Steatotic Liver Disease trials in other cities
- San Antonio, TX17 studies
- New York City, NY16 studies
- Miami, FL16 studies
- San Diego, CA14 studies
- Austin, TX13 studies
- Houston, TX13 studies
- Richmond, VA12 studies
- Chandler, AZ10 studies
- Tucson, AZ10 studies
- Hialeah, FL9 studies
- Dallas, TX9 studies
- St. Louis, MO9 studies
Other studies in Kansas City
- Breast Cancer34 studies
- Non-Small Cell Lung Cancer31 studies
- Heart Failure25 studies
- Cancer (all types)21 studies
- Lung Cancer19 studies
- Colorectal Cancer16 studies
- Metastatic Cancer15 studies
- Acute Myeloid Leukemia15 studies
- Prostate Cancer14 studies
- Ovarian Cancer11 studies
- Obesity11 studies
- Type 2 Diabetes11 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.